Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-OCT imaging of benralizumab tracer in severe asthma
NL-OMON58093Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of benralizumab in asthma and eosinophilic asthma (EA) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility of in vivo imaging of benralizumab-800CW using immuno-OCT. Started Aug 2026; status: recruiting.
02
Drugs
benralizumab
03
Conditions
asthmaeosinophilic asthma (EA)
Beyond the preview
Go deeper on NL-OMON58093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58093.